Pliant Therapeutics, Inc. (PLRX) SEC Filings — 2025
14 SEC filings for Pliant Therapeutics, Inc. (PLRX) in 2025.
Filings
- Pliant Therapeutics Appoints New Directors, Adjusts Executive Pay — 8-K · Dec 16, 2025
- Pliant Therapeutics Appoints New CMO and CSO — 8-K · Dec 8, 2025
- PLRX Narrows Losses Amid R&D Cuts After Bexotegrast Failure — 10-Q · Nov 6, 2025
- Pliant Therapeutics Announces Executive and Director Changes — 8-K · Oct 24, 2025
- Pliant Therapeutics Terminates Material Definitive Agreement — 8-K · Oct 20, 2025
- Pliant's Q2 Loss Widens to $49.7M Amid R&D Surge — 10-Q · Aug 7, 2025
- Pliant Therapeutics Files 8-K for Corporate Updates — 8-K · Jun 9, 2025
- Pliant Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025
- Pliant Therapeutics Files 8-K on Executive Changes & Exit Costs — 8-K · May 1, 2025
- Pliant Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 23, 2025
- Pliant Therapeutics Files 8-K: Material Agreements & Bylaw Changes — 8-K · Mar 13, 2025
- Pliant Therapeutics Files 2024 10-K — 10-K · Mar 3, 2025
- Pliant Therapeutics Files 8-K — 8-K · Feb 13, 2025
- Pliant Therapeutics Files 8-K — 8-K · Feb 10, 2025